NRG-GU011

A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy with or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

Principal Investigator

Bridget Koontz, MD

Status

Disease Site

Genitourinary [GU] Prostate

Phase

II

Developmental Therapeutics

Yes

Primary Objective

Compare conventional radiological progression-free
survival (rPFS) for positron emission tomography (PET)-detected, biochemically
recurrent, oligometastatic, castration-sensitive prostate cancer patients treated
with SABR plus placebo vs. SABR plus relugolix.

Patient Population

Pathologically proven diagnosis of prostate adenocarcinoma and are recurrent oligometastatic.

Target Accrual

194